vs
Asana, Inc.（ASAN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Asana, Inc.的1.0倍（$207.3M vs $201.0M），Asana, Inc.净利率更高（-34.0% vs -62.0%，领先28.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.3%），Asana, Inc.自由现金流更多（$15.5M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 8.4%）
Asana是一家总部位于美国旧金山的软件企业，由达斯汀·莫斯科维茨和贾斯汀·罗森斯坦于2008年创立，核心产品是同名工作管理平台，支持网页端与移动端使用，可帮助团队梳理、跟踪及统筹各类工作事项，2012年4月正式商业化推出，2020年9月直接上市，当时估值达55亿美元。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ASAN vs RARE — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $201.0M | $207.3M |
| 净利润 | $-68.4M | $-128.6M |
| 毛利率 | 88.9% | — |
| 营业利润率 | -34.8% | -54.7% |
| 净利率 | -34.0% | -62.0% |
| 营收同比 | 9.3% | 25.9% |
| 净利润同比 | -19.4% | 3.5% |
| 每股收益（稀释后） | $-0.29 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $201.0M | $207.3M | ||
| Q3 25 | $196.9M | $159.9M | ||
| Q2 25 | $187.3M | $166.5M | ||
| Q1 25 | $188.3M | $139.3M | ||
| Q4 24 | $183.9M | $164.6M | ||
| Q3 24 | $179.2M | $139.5M | ||
| Q2 24 | $172.4M | $147.0M | ||
| Q1 24 | $171.1M | $108.8M |
| Q4 25 | $-68.4M | $-128.6M | ||
| Q3 25 | $-48.4M | $-180.4M | ||
| Q2 25 | $-40.0M | $-115.0M | ||
| Q1 25 | $-62.3M | $-151.1M | ||
| Q4 24 | $-57.3M | $-133.2M | ||
| Q3 24 | $-72.2M | $-133.5M | ||
| Q2 24 | $-63.7M | $-131.6M | ||
| Q1 24 | $-62.4M | $-170.7M |
| Q4 25 | 88.9% | — | ||
| Q3 25 | 89.7% | — | ||
| Q2 25 | 89.7% | — | ||
| Q1 25 | 89.6% | — | ||
| Q4 24 | 89.2% | — | ||
| Q3 24 | 88.8% | — | ||
| Q2 24 | 89.7% | — | ||
| Q1 24 | 89.8% | — |
| Q4 25 | -34.8% | -54.7% | ||
| Q3 25 | -25.1% | -106.9% | ||
| Q2 25 | -23.4% | -64.8% | ||
| Q1 25 | -33.8% | -102.6% | ||
| Q4 24 | -32.7% | -74.3% | ||
| Q3 24 | -42.9% | -94.6% | ||
| Q2 24 | -38.4% | -79.1% | ||
| Q1 24 | -39.7% | -151.9% |
| Q4 25 | -34.0% | -62.0% | ||
| Q3 25 | -24.6% | -112.8% | ||
| Q2 25 | -21.4% | -69.0% | ||
| Q1 25 | -33.1% | -108.5% | ||
| Q4 24 | -31.2% | -80.9% | ||
| Q3 24 | -40.3% | -95.7% | ||
| Q2 24 | -37.0% | -89.5% | ||
| Q1 24 | -36.5% | -156.8% |
| Q4 25 | $-0.29 | $-1.28 | ||
| Q3 25 | $-0.20 | $-1.81 | ||
| Q2 25 | $-0.17 | $-1.17 | ||
| Q1 25 | $-0.27 | $-1.57 | ||
| Q4 24 | $-0.25 | $-1.34 | ||
| Q3 24 | $-0.31 | $-1.40 | ||
| Q2 24 | $-0.28 | $-1.52 | ||
| Q1 24 | $-0.28 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $183.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $188.4M | $-80.0M |
| 总资产 | $840.4M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $183.5M | $421.0M | ||
| Q3 25 | $184.1M | $202.5M | ||
| Q2 25 | $193.8M | $176.3M | ||
| Q1 25 | $184.7M | $127.1M | ||
| Q4 24 | $196.8M | $174.0M | ||
| Q3 24 | $219.4M | $150.6M | ||
| Q2 24 | $222.0M | $480.7M | ||
| Q1 24 | $236.7M | $112.3M |
| Q4 25 | $188.4M | $-80.0M | ||
| Q3 25 | $224.6M | $9.2M | ||
| Q2 25 | $236.3M | $151.3M | ||
| Q1 25 | $227.5M | $144.2M | ||
| Q4 24 | $239.3M | $255.0M | ||
| Q3 24 | $291.9M | $346.8M | ||
| Q2 24 | $319.9M | $432.4M | ||
| Q1 24 | $326.4M | $140.3M |
| Q4 25 | $840.4M | $1.5B | ||
| Q3 25 | $883.2M | $1.2B | ||
| Q2 25 | $877.1M | $1.3B | ||
| Q1 25 | $891.4M | $1.3B | ||
| Q4 24 | $874.2M | $1.5B | ||
| Q3 24 | $945.4M | $1.5B | ||
| Q2 24 | $978.2M | $1.6B | ||
| Q1 24 | $962.0M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $15.5M | $-100.8M |
| 自由现金流率自由现金流/营收 | 7.7% | -48.6% |
| 资本支出强度资本支出/营收 | 0.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $74.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $16.2M | $-99.8M | ||
| Q3 25 | $39.8M | $-91.4M | ||
| Q2 25 | $6.8M | $-108.3M | ||
| Q1 25 | $15.9M | $-166.5M | ||
| Q4 24 | $-14.9M | $-79.3M | ||
| Q3 24 | $15.9M | $-67.0M | ||
| Q2 24 | $-1.9M | $-77.0M | ||
| Q1 24 | $-15.3M | $-190.7M |
| Q4 25 | $15.5M | $-100.8M | ||
| Q3 25 | $38.5M | $-92.7M | ||
| Q2 25 | $6.1M | $-110.7M | ||
| Q1 25 | $14.3M | $-167.8M | ||
| Q4 24 | $-16.3M | $-79.5M | ||
| Q3 24 | $14.2M | $-68.6M | ||
| Q2 24 | $-2.9M | $-79.0M | ||
| Q1 24 | $-15.8M | $-193.9M |
| Q4 25 | 7.7% | -48.6% | ||
| Q3 25 | 19.6% | -58.0% | ||
| Q2 25 | 3.3% | -66.5% | ||
| Q1 25 | 7.6% | -120.5% | ||
| Q4 24 | -8.8% | -48.3% | ||
| Q3 24 | 7.9% | -49.2% | ||
| Q2 24 | -1.7% | -53.7% | ||
| Q1 24 | -9.3% | -178.2% |
| Q4 25 | 0.3% | 0.5% | ||
| Q3 25 | 0.7% | 0.8% | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.8% | 1.0% | ||
| Q4 24 | 0.7% | 0.1% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 0.6% | 1.4% | ||
| Q1 24 | 0.3% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASAN
| US | $118.5M | 59% |
| Non Us | $82.5M | 41% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
